Current Diagnosis and Management of Tangier Disease
- PMID: 33994407
- PMCID: PMC8326168
- DOI: 10.5551/jat.RV17053
Current Diagnosis and Management of Tangier Disease
Abstract
Tangier disease is a genetic disorder characterized by an absence or extremely low level of high-density lipoprotein (HDL)-cholesterol (HDL-C). It is caused by a dysfunctional mutation of the ATP-binding cassette transporter A1 (ABCA1) gene, the mandatory gene for generation of HDL particles from cellular cholesterol and phospholipids, and it appears in an autosomal recessive hereditary profile. To date, 35 cases have been reported in Japan and 109 cases outside Japan. With dysfunctional mutations in both alleles (homozygotes or compound heterozygotes), the HDL-C level is mostly less than 5 mg/dL and there is 10 mg/dL or less of apolipoprotein A-I (apoA-I), the major protein component of HDL. In patients with Tangier disease, major physical findings are orange-colored pharyngeal tonsils, hepatosplenomegaly, corneal opacity, lymphadenopathy, and peripheral neuropathy. Although patients tend to have decreased low-density lipoprotein (LDL)-cholesterol (LDL-C) levels, premature coronary artery disease is frequently observed. No specific curative treatment is currently available, so early identification of patients and preventing atherosclerosis development are crucial. Management of risk factors other than low HDL-C is also important, such as LDL-C levels, hypertension and smoking. Additionally, treatment for glucose intolerance might be required because impaired insulin secretion from pancreatic beta cells has occasionally been reported.
Keywords: ABCA1; Atherosclerosis; Cholesterol efflux; HDL; Orange tonsil; Reverse cholesterol transport; Tangier disease.
Figures





Similar articles
-
Genetic and Functional Analyses of Patients with Marked Hypo-High-Density Lipoprotein Cholesterolemia.J Atheroscler Thromb. 2024 Sep 1;31(9):1304-1318. doi: 10.5551/jat.64579. Epub 2024 Mar 28. J Atheroscler Thromb. 2024. PMID: 38538338 Free PMC article.
-
Tangier disease: epidemiology, pathophysiology, and management.Am J Cardiovasc Drugs. 2012 Oct 1;12(5):303-11. doi: 10.2165/11634140-000000000-00000. Am J Cardiovasc Drugs. 2012. PMID: 22913675
-
Homozygous Tangier disease and cardiovascular disease.Atherosclerosis. 1994 May;107(1):85-98. doi: 10.1016/0021-9150(94)90144-9. Atherosclerosis. 1994. PMID: 7945562 Review.
-
Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).J Clin Invest. 1982 Nov;70(5):934-45. doi: 10.1172/jci110705. J Clin Invest. 1982. PMID: 7130397 Free PMC article.
-
[The role of transmembrane lipidtransporter molecules in the atherosclerotic process].Orv Hetil. 2006 Feb 12;147(6):251-7. Orv Hetil. 2006. PMID: 16610615 Review. Hungarian.
Cited by
-
A rare case of nephrotic syndrome and Tangier disease.CEN Case Rep. 2023 Aug;12(3):265-269. doi: 10.1007/s13730-022-00761-8. Epub 2022 Dec 10. CEN Case Rep. 2023. PMID: 36496495 Free PMC article.
-
A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway.Chin Med. 2023 Jun 15;18(1):72. doi: 10.1186/s13020-023-00758-0. Chin Med. 2023. PMID: 37322486 Free PMC article.
-
Genetic and Functional Analyses of Patients with Marked Hypo-High-Density Lipoprotein Cholesterolemia.J Atheroscler Thromb. 2024 Sep 1;31(9):1304-1318. doi: 10.5551/jat.64579. Epub 2024 Mar 28. J Atheroscler Thromb. 2024. PMID: 38538338 Free PMC article.
-
A Low Level of High-Density Lipoprotein Cholesterol Predicts All-Cause Mortality Within 30 Days in Hospitalized Elderly Patients.Cureus. 2025 Apr 22;17(4):e82805. doi: 10.7759/cureus.82805. eCollection 2025 Apr. Cureus. 2025. PMID: 40406779 Free PMC article.
-
Etiologic Puzzle of Coronary Artery Disease: How Important Is Genetic Component?Life (Basel). 2022 Jun 9;12(6):865. doi: 10.3390/life12060865. Life (Basel). 2022. PMID: 35743896 Free PMC article. Review.
References
-
- Assmann G, Eckardstein A, Brewer HB. Familial analphalipoproteinemia: Tangier disease. The Metabolic and Molecular Bases of Inherited Diseases (McGraw Hill), 2001; 8th ed. vol 2: 2937-2960
-
- Fredrickson DS, Altrocchi PH, Avioli LV, Goodman DS, Goodman HC. Tangier disease.Combined clinical staff conference at the National Institutes of Health. Ann Intern Med, 1961; 55: 1016-1031
-
- Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high-density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem, 1991; 266: 3080-3086 - PubMed
-
- Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR . Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet, 1999; 22: 336-345 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources